Bihua Chen - Net Worth and Insider Trading

Bihua Chen Net Worth

The estimated net worth of Bihua Chen is at least $442 Million dollars as of 2024-11-05. Bihua Chen is the 10% Owner of MoonLake Immunotherapeutics and owns about 8,494,151 shares of MoonLake Immunotherapeutics (MLTX) stock worth over $396 Million. Bihua Chen is the Director of Erasca Inc and owns about 10,813,246 shares of Erasca Inc (ERAS) stock worth over $30 Million. Bihua Chen is also the CEO and Chairperson, 10% Owner of Helix Acquisition Corp II and owns about 903,600 shares of Helix Acquisition Corp II (HLXB) stock worth over $10 Million. Besides these, Bihua Chen also holds Helix Acquisition Corp (HLXA) . Details can be seen in Bihua Chen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Bihua Chen has not made any transactions after 2024-02-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Bihua Chen

Bihua Chen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Bihua Chen owns 37 companies in total, including Helix Acquisition Corp (HLXA) , Akouos Inc (AKUS) , and Avidity Biosciences Inc (RNA) among others .

Click here to see the complete history of Bihua Chen’s form 4 insider trades.

Insider Ownership Summary of Bihua Chen

Ticker	Comapny	Transaction Date	Type of Owner
HLXA	Helix Acquisition Corp	2020-10-22	director & 10 percent owner & CEO and Chairman
AKUS	Akouos Inc	2020-06-25	director & 10 percent owner
RNA	Avidity Biosciences Inc	2020-06-11	director & 10 percent owner
		2019-04-22	director & 10 percent owner
		2018-10-30	director & 10 percent owner
		2018-07-18	director & 10 percent owner
		2018-06-20	director & 10 percent owner
		2018-05-23	director & 10 percent owner
		2017-12-14	director & 10 percent owner
		2017-11-08	director & 10 percent owner
		2016-06-01	director & 10 percent owner
		2014-08-15	director & 10 percent owner
		2016-11-03	director & 10 percent owner
		2020-10-29	director & 10 percent owner
		2021-03-11	director & 10 percent owner
		2021-04-22	director & 10 percent owner
		2020-11-18	director & 10 percent owner
		2022-12-20	director
		2021-10-07	10 percent owner
		2021-06-24	10 percent owner
		2021-07-28	10 percent owner
		2023-04-20	10 percent owner
		2021-06-29	10 percent owner
		2021-03-25	director & 10 percent owner
		2023-10-05	10 percent owner
		2021-06-23	director & 10 percent owner
		2020-12-15	director & 10 percent owner
		2022-01-06	10 percent owner
		2023-03-30	director & 10 percent owner
		2021-06-16	director & 10 percent owner
		2021-10-20	10 percent owner
		2021-09-14	10 percent owner
		2016-11-03	director & 10 percent owner
		2023-03-03	10 percent owner
		2023-05-29	other: See below
		2023-05-29	other: See below
		2023-10-23	10 percent owner

Bihua Chen Latest Holdings Summary

Bihua Chen currently owns a total of 4 stocks. Among these stocks, Bihua Chen owns 8,494,151 shares of MoonLake Immunotherapeutics (MLTX) as of October 5, 2023, with a value of $396 Million and a weighting of 89.65%. Bihua Chen owns 10,813,246 shares of Erasca Inc (ERAS) as of December 13, 2022, with a value of $30 Million and a weighting of 6.9%. Bihua Chen also owns 903,600 shares of Helix Acquisition Corp II (HLXB) as of February 13, 2024, with a value of $10 Million and a weighting of 2.16%. The other 1 stocks Helix Acquisition Corp (HLXA) have a combined weighting of 1.29% among all his current holdings.

Latest Holdings of Bihua Chen

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
MLTX	MoonLake Immunotherapeutics	2023-10-05	8,494,151	46.64	396,167,203
ERAS	Erasca Inc	2022-12-13	10,813,246	2.82	30,493,354
HLXB	Helix Acquisition Corp II	2024-02-13	903,600	10.55	9,532,980
HLXA	Helix Acquisition Corp	2020-10-22	430,000	13.25	5,697,500

Holding Weightings of Bihua Chen

Bihua Chen Form 4 Trading Tracker

According to the SEC Form 4 filings, Bihua Chen has made a total of 5 transactions in MoonLake Immunotherapeutics (MLTX) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in MoonLake Immunotherapeutics is the acquisition of 58,839 shares on October 5, 2023, which cost Bihua Chen around $4 Million.

According to the SEC Form 4 filings, Bihua Chen has made a total of 4 transactions in Erasca Inc (ERAS) over the past 5 years, including 3 buys and 1 sells. The most-recent trade in Erasca Inc is the acquisition of 307,692 shares on December 13, 2022, which cost Bihua Chen around $2 Million.

According to the SEC Form 4 filings, Bihua Chen has made a total of 1 transactions in Helix Acquisition Corp II (HLXB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Helix Acquisition Corp II is the acquisition of 2,400,000 shares on February 13, 2024, which cost Bihua Chen around $24 Million.

More details on Bihua Chen's insider transactions can be found in the Insider Trading History of Bihua Chen table.

Insider Trading History of Bihua Chen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Bihua Chen Trading Performance

GuruFocus tracks the stock performance after each of Bihua Chen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bihua Chen is -5.25%. GuruFocus also compares Bihua Chen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bihua Chen within 3 months outperforms 2 times out of 9 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Bihua Chen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Bihua Chen

Average Return

Average return per transaction

Outperforming Transactions

1 out of 8 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-3.44
Relative Return to S&P 500(%)	-5.68

Bihua Chen Ownership Network

Ownership Network List of Bihua Chen

No Data

Ownership Network Relation of Bihua Chen

Bihua Chen Owned Company Details

What does Helix Acquisition Corp do?

Who are the key executives at Helix Acquisition Corp?

Bihua Chen is the director & 10 percent owner & CEO and Chairman of Helix Acquisition Corp. Other key executives at Helix Acquisition Corp include director & 10 percent owner Helix Holdings Llc , and Chief Financial Officer Jay Scollins .

Helix Acquisition Corp (HLXA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Helix Acquisition Corp (HLXA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Helix Acquisition Corp (HLXA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Helix Acquisition Corp (HLXA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Helix Acquisition Corp Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Bihua Chen is the director & 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Avidity Biosciences Inc do?

Who are the key executives at Avidity Biosciences Inc?

Bihua Chen is the director & 10 percent owner of Avidity Biosciences Inc. Other key executives at Avidity Biosciences Inc include Chief Scientific Officer Arthur A Levin , Chief Human Resources Officer Teresa Mccarthy , and Chief Technical Officer W. Michael Flanagan .

Avidity Biosciences Inc (RNA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Avidity Biosciences Inc (RNA). Other recent insider transactions involving Avidity Biosciences Inc (RNA) include a net sale of 189,500 shares made by Arthur A Levin , a net sale of 622,046 shares made by Sarah Boyce , and a net sale of 243,599 shares made by Michael F Maclean .

In summary, during the past 3 months, insiders sold 379,437 shares of Avidity Biosciences Inc (RNA) in total and bought 0 shares, with a net sale of 379,437 shares. During the past 18 months, 1,373,356 shares of Avidity Biosciences Inc (RNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,373,356 shares.

Avidity Biosciences Inc (RNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avidity Biosciences Inc Insider Transactions

No Available Data

What does Turning Point Therapeutics Inc do?

Who are the key executives at Turning Point Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Turning Point Therapeutics Inc. Other key executives at Turning Point Therapeutics Inc include EVP & Chief Financial Officer Paolo Tombesi , SVP & Chief Commercial Officer Steve M Sabus , and SVP & General Counsel Brian Sun .

Turning Point Therapeutics Inc (TPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Turning Point Therapeutics Inc (TPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Turning Point Therapeutics Inc (TPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Turning Point Therapeutics Inc (TPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Turning Point Therapeutics Inc Insider Transactions

No Available Data

What does Axonics Inc do?

Who are the key executives at Axonics Inc?

Bihua Chen is the director & 10 percent owner of Axonics Inc. Other key executives at Axonics Inc include Chief Financial Officer Kari Leigh Keese , Chief Medical Officer Karen Noblett , and director & Chief Executive Officer Raymond W Cohen .

Axonics Inc (AXNX) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Axonics Inc (AXNX). Other recent insider transactions involving Axonics Inc (AXNX) include a net sale of 35,287 shares made by Karen Noblett , a net sale of 32,884 shares made by Ford Alfred J Jr , and a net sale of 15,674 shares made by Danny L. Dearen .

In summary, during the past 3 months, insiders sold 2,961 shares of Axonics Inc (AXNX) in total and bought 0 shares, with a net sale of 2,961 shares. During the past 18 months, 141,355 shares of Axonics Inc (AXNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 141,355 shares.

Axonics Inc (AXNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Axonics Inc Insider Transactions

No Available Data

What does Constellation Pharmaceuticals Inc do?

Who are the key executives at Constellation Pharmaceuticals Inc?

Bihua Chen is the director & 10 percent owner of Constellation Pharmaceuticals Inc. Other key executives at Constellation Pharmaceuticals Inc include Chief Financial Officer Emma Reeve , 10 percent owner Column Group L P , and See Remarks Karen Valentine .

Constellation Pharmaceuticals Inc (CNST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Constellation Pharmaceuticals Inc (CNST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Constellation Pharmaceuticals Inc (CNST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Constellation Pharmaceuticals Inc (CNST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Constellation Pharmaceuticals Inc Insider Transactions

No Available Data

What does Kezar Life Sciences Inc do?

Who are the key executives at Kezar Life Sciences Inc?

Bihua Chen is the director & 10 percent owner of Kezar Life Sciences Inc. Other key executives at Kezar Life Sciences Inc include 10 percent owner Morningside Venture Investments Ltd , Chief Business Officer Nicholas Michael Mordwinkin , and 10 percent owner Equal Talent Investments Ltd .

Kezar Life Sciences Inc (KZR) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Kezar Life Sciences Inc (KZR). Other recent insider transactions involving Kezar Life Sciences Inc (KZR) include a net sale of 6,688 shares made by ,

In summary, during the past 3 months, insiders sold 0 shares of Kezar Life Sciences Inc (KZR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 669 shares of Kezar Life Sciences Inc (KZR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 669 shares.

Kezar Life Sciences Inc (KZR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kezar Life Sciences Inc Insider Transactions

No Available Data

What does Kiniksa Pharmaceuticals International PLC do?

Who are the key executives at Kiniksa Pharmaceuticals International PLC?

Bihua Chen is the director & 10 percent owner of Kiniksa Pharmaceuticals International PLC. Other key executives at Kiniksa Pharmaceuticals International PLC include Chief Business Officer Eben Tessari , Group VP & Rilonacept GM Ross Moat , and Chief Medical Officer John Paolini .

Kiniksa Pharmaceuticals International PLC (KNSA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Kiniksa Pharmaceuticals International PLC (KNSA). Other recent insider transactions involving Kiniksa Pharmaceuticals International PLC (KNSA) include a net sale of 150,848 shares made by John Paolini , a net sale of 219,460 shares made by Sanj K Patel , and a net sale of 52,000 shares made by Eben Tessari .

In summary, during the past 3 months, insiders sold 181,198 shares of Kiniksa Pharmaceuticals International PLC (KNSA) in total and bought 0 shares, with a net sale of 181,198 shares. During the past 18 months, 539,163 shares of Kiniksa Pharmaceuticals International PLC (KNSA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 539,163 shares.

Kiniksa Pharmaceuticals International PLC (KNSA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kiniksa Pharmaceuticals International PLC Insider Transactions

No Available Data

What does Proteostasis Therapeutics Inc do?

Who are the key executives at Proteostasis Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Proteostasis Therapeutics Inc. Other key executives at Proteostasis Therapeutics Inc include Interim Head of Finance Michael Alfieri , director & President and CEO Meenu Chhabra , and See Remarks Eric D Larson .

Proteostasis Therapeutics Inc (PTI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Proteostasis Therapeutics Inc (PTI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Proteostasis Therapeutics Inc (PTI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Proteostasis Therapeutics Inc (PTI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Proteostasis Therapeutics Inc Insider Transactions

No Available Data

What does Apellis Pharmaceuticals Inc do?

Who are the key executives at Apellis Pharmaceuticals Inc?

Bihua Chen is the director & 10 percent owner of Apellis Pharmaceuticals Inc. Other key executives at Apellis Pharmaceuticals Inc include See Remarks James George Chopas , Chief Operating Officer Pascal Deschatelets , and Chief Financial Officer Timothy Eugene Sullivan .

Apellis Pharmaceuticals Inc (APLS) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Apellis Pharmaceuticals Inc (APLS). Other recent insider transactions involving Apellis Pharmaceuticals Inc (APLS) include a net sale of 308,688 shares made by Pascal Deschatelets , a net sale of 463,087 shares made by Cedric Francois , and a net sale of 102,839 shares made by Timothy Eugene Sullivan .

In summary, during the past 3 months, insiders sold 37,742 shares of Apellis Pharmaceuticals Inc (APLS) in total and bought 0 shares, with a net sale of 37,742 shares. During the past 18 months, 1,275,451 shares of Apellis Pharmaceuticals Inc (APLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,275,451 shares.

Apellis Pharmaceuticals Inc (APLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Apellis Pharmaceuticals Inc Insider Transactions

No Available Data

What does Clearside Biomedical Inc do?

Who are the key executives at Clearside Biomedical Inc?

Bihua Chen is the director & 10 percent owner of Clearside Biomedical Inc. Other key executives at Clearside Biomedical Inc include 10 percent owner Bradford T Whitmore , Chief Financial Officer Charles A. Deignan , and director & 10 percent owner Clay Thorp .

Clearside Biomedical Inc (CLSD) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Clearside Biomedical Inc (CLSD). Other recent insider transactions involving Clearside Biomedical Inc (CLSD) include a net purchase of 90,000 shares made by , a net purchase of 580,222 shares made by Bradford T Whitmore , and a net purchase of 100,000 shares made by Anthony S Gibney .

In summary, during the past 3 months, insiders sold 0 shares of Clearside Biomedical Inc (CLSD) in total and bought 36,500 shares, with a net purchase of 36,500 shares. During the past 18 months, 30,900 shares of Clearside Biomedical Inc (CLSD) were sold and 798,035 shares were bought by its insiders, resulting in a net purchase of 767,135 shares.

Clearside Biomedical Inc (CLSD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Clearside Biomedical Inc Insider Transactions

No Available Data

What does Cellectar Biosciences Inc do?

Who are the key executives at Cellectar Biosciences Inc?

Bihua Chen is the director & 10 percent owner of Cellectar Biosciences Inc. Other key executives at Cellectar Biosciences Inc include Senior Vice President & Medical Andrei Shustov , Chief Commercial Officer Darrell Shane Lea , and Chief Financial Officer Chad J Kolean .

Cellectar Biosciences Inc (CLRB) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cellectar Biosciences Inc (CLRB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cellectar Biosciences Inc (CLRB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cellectar Biosciences Inc (CLRB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cellectar Biosciences Inc Insider Transactions

No Available Data

What does Yumanity Therapeutics Inc do?

Who are the key executives at Yumanity Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Yumanity Therapeutics Inc. Other key executives at Yumanity Therapeutics Inc include director & Chief Executive Officer Shawn Iadonato , Chief Scientific Officer Thierry Guillaudeux , and Chief Financial Officer Keith Baker .

Yumanity Therapeutics Inc (YMTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Yumanity Therapeutics Inc (YMTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Yumanity Therapeutics Inc (YMTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Yumanity Therapeutics Inc (YMTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Yumanity Therapeutics Inc Insider Transactions

No Available Data

What does Atea Pharmaceuticals Inc do?

Who are the key executives at Atea Pharmaceuticals Inc?

Bihua Chen is the director & 10 percent owner of Atea Pharmaceuticals Inc. Other key executives at Atea Pharmaceuticals Inc include director & 10 percent owner & President & CEO & and Chairman Jean-pierre Sommadossi , See Remarks Andrea Corcoran , and See Remarks Wayne Foster .

Atea Pharmaceuticals Inc (AVIR) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Atea Pharmaceuticals Inc (AVIR). Other recent insider transactions involving Atea Pharmaceuticals Inc (AVIR) include a net sale of 115,885 shares made by Jean-pierre Sommadossi , a net sale of 17,544 shares made by Bruce Polsky , and a net sale of 15,870 shares made by Maria Arantxa Horga .

In summary, during the past 3 months, insiders sold 57,969 shares of Atea Pharmaceuticals Inc (AVIR) in total and bought 0 shares, with a net sale of 57,969 shares. During the past 18 months, 203,467 shares of Atea Pharmaceuticals Inc (AVIR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 203,467 shares.

Atea Pharmaceuticals Inc (AVIR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Atea Pharmaceuticals Inc Insider Transactions

No Available Data

What does Prometheus Biosciences Inc do?

Who are the key executives at Prometheus Biosciences Inc?

Bihua Chen is the director & 10 percent owner of Prometheus Biosciences Inc. Other key executives at Prometheus Biosciences Inc include Chief Financial Officer Keith W Marshall , director & President and CEO Mark C. Mckenna , and 10 percent owner Cedars Sinai Intellectual Property Co .

Prometheus Biosciences Inc (RXDX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Prometheus Biosciences Inc (RXDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Prometheus Biosciences Inc (RXDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Prometheus Biosciences Inc (RXDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prometheus Biosciences Inc Insider Transactions

No Available Data

What does Rain Oncology Inc do?

Who are the key executives at Rain Oncology Inc?

Bihua Chen is the director & 10 percent owner of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Management Llc .

Rain Oncology Inc (RAIN) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net purchase of 1,198,445 shares made by Kevin C Tang , and a net sale of 995,000 shares made by Boxer Capital, Llc .

In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,168,973 shares of Rain Oncology Inc (RAIN) were sold and 1,372,418 shares were bought by its insiders, resulting in a net purchase of 203,445 shares.

Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rain Oncology Inc Insider Transactions

No Available Data

What does Olema Pharmaceuticals inc do?

Who are the key executives at Olema Pharmaceuticals inc?

Bihua Chen is the director & 10 percent owner of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include 10 percent owner Paradigm Biocapital Advisors Lp , director & Chief Technology Officer Cyrus Harmon , and director & President and CEO Sean Bohen .

Olema Pharmaceuticals inc (OLMA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 338,181 shares made by Cyrus Harmon , a net sale of 44,370 shares made by David C. Myles , and a net sale of 2,300,000 shares made by Paradigm Biocapital Advisors Lp .

In summary, during the past 3 months, insiders sold 0 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,048,074 shares of Olema Pharmaceuticals inc (OLMA) were sold and 2,245,932 shares were bought by its insiders, resulting in a net sale of 1,802,142 shares.

Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Olema Pharmaceuticals inc Insider Transactions

No Available Data

What does Erasca Inc do?

Who are the key executives at Erasca Inc?

Bihua Chen is the director of Erasca Inc. Other key executives at Erasca Inc include director & 10 percent owner & See Remarks Jonathan E Lim , Chief Medical Officer Shannon Morris , and General Counsel Ebun Garner .

Erasca Inc (ERAS) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Erasca Inc (ERAS). Other recent insider transactions involving Erasca Inc (ERAS) include a net purchase of 2,100,000 shares made by Jonathan E Lim , a net purchase of 110,000 shares made by Alexander W. Casdin , and a net purchase of 10,000 shares made by Start Valerie Denise Harding .

In summary, during the past 3 months, insiders sold 0 shares of Erasca Inc (ERAS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Erasca Inc (ERAS) were sold and 2,220,000 shares were bought by its insiders, resulting in a net purchase of 2,220,000 shares.

Erasca Inc (ERAS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Erasca Inc Insider Transactions

No Available Data

What does Pyxis Oncology Inc do?

Who are the key executives at Pyxis Oncology Inc?

Bihua Chen is the 10 percent owner of Pyxis Oncology Inc. Other key executives at Pyxis Oncology Inc include Chief Financial Officer Pamela Ann Connealy , Chief Accounting Officer Jitendra Wadhane , and director & Chief Executive Officer Lara Sullivan .

Pyxis Oncology Inc (PYXS) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Pyxis Oncology Inc (PYXS). Other recent insider transactions involving Pyxis Oncology Inc (PYXS) include a net purchase of 31,426 shares made by Pamela Ann Connealy , a net purchase of 10,000 shares made by Jitendra Wadhane , and a net sale of 36,558 shares made by Lara Sullivan .

In summary, during the past 3 months, insiders sold 0 shares of Pyxis Oncology Inc (PYXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 36,558 shares of Pyxis Oncology Inc (PYXS) were sold and 41,426 shares were bought by its insiders, resulting in a net purchase of 4,868 shares.

Pyxis Oncology Inc (PYXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pyxis Oncology Inc Insider Transactions

No Available Data

What does Elevation Oncology Inc do?

Who are the key executives at Elevation Oncology Inc?

Bihua Chen is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Venbio Global Strategic Gp Iii, L.p. , and 10 percent owner Venbio Global Strategic Fund Iii, L.p. .

Elevation Oncology Inc (ELEV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Elevation Oncology Inc Insider Transactions

No Available Data

What does Icosavax Inc do?

Who are the key executives at Icosavax Inc?

Bihua Chen is the 10 percent owner of Icosavax Inc. Other key executives at Icosavax Inc include director & Chief Executive Officer Adam K. Simpson , Chief Medical Officer Niranjan Kanesa-thasan , and Chief Financial Officer Thomas Joseph Russo .

Icosavax Inc (ICVX) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Icosavax Inc (ICVX). Other recent insider transactions involving Icosavax Inc (ICVX) include a net sale of 193,993 shares made by Adam K. Simpson , a net sale of 28,581 shares made by Cassia Cearley , and a net sale of 18,249 shares made by Thomas Joseph Russo .

In summary, during the past 3 months, insiders sold 0 shares of Icosavax Inc (ICVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 272,386 shares of Icosavax Inc (ICVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 272,386 shares.

Icosavax Inc (ICVX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Icosavax Inc Insider Transactions

No Available Data

What does Immuneering Corp do?

Who are the key executives at Immuneering Corp?

Bihua Chen is the 10 percent owner of Immuneering Corp. Other key executives at Immuneering Corp include 10 percent owner Cormorant Asset Management, Lp , Vice President & Finance Mallory Morales , and Chief Business Officer Harold Eugene Brakewood .

Immuneering Corp (IMRX) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Immuneering Corp (IMRX). Other recent insider transactions involving Immuneering Corp (IMRX) include a net sale of 1,309,091 shares made by Cormorant Asset Management, Lp , a net purchase of 100,000 shares made by Peter Feinberg , and a net purchase of 57,965 shares made by Ann E Berman .

In summary, during the past 3 months, insiders sold 0 shares of Immuneering Corp (IMRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,309,091 shares of Immuneering Corp (IMRX) were sold and 197,083 shares were bought by its insiders, resulting in a net sale of 1,112,008 shares.

Immuneering Corp (IMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immuneering Corp Insider Transactions

No Available Data

What does Aerovate Therapeutics Inc do?

Who are the key executives at Aerovate Therapeutics Inc?

Bihua Chen is the 10 percent owner of Aerovate Therapeutics Inc. Other key executives at Aerovate Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , See Remarks George A Eldridge , and SENIOR VICE PRESIDENT & CMC Marinus Verwijs .

Aerovate Therapeutics Inc (AVTE) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Aerovate Therapeutics Inc (AVTE). Other recent insider transactions involving Aerovate Therapeutics Inc (AVTE) include a net sale of 64,255 shares made by Hunter Gillies , a net sale of 142,001 shares made by Benjamin T Dake , and a net sale of 62,449 shares made by Timothy P Noyes .

In summary, during the past 3 months, insiders sold 0 shares of Aerovate Therapeutics Inc (AVTE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 401,833 shares of Aerovate Therapeutics Inc (AVTE) were sold and 928,110 shares were bought by its insiders, resulting in a net purchase of 526,277 shares.

Aerovate Therapeutics Inc (AVTE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerovate Therapeutics Inc Insider Transactions

No Available Data

What does Design Therapeutics Inc do?

Who are the key executives at Design Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Design Therapeutics Inc. Other key executives at Design Therapeutics Inc include director & President and CEO Joao Md Siffert , director & 10 percent owner Simeon George , and 10 percent owner Sr One Capital Fund I Aggregator Lp .

Design Therapeutics Inc (DSGN) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Design Therapeutics Inc (DSGN). Other recent insider transactions involving Design Therapeutics Inc (DSGN) include a net purchase of 1,420,126 shares made by Arsani William , a net purchase of 26,965 shares made by John P. Schmid , and a net purchase of 21,000 shares made by Rodney W Lappe .

In summary, during the past 3 months, insiders sold 814,874 shares of Design Therapeutics Inc (DSGN) in total and bought 0 shares, with a net sale of 814,874 shares. During the past 18 months, 814,874 shares of Design Therapeutics Inc (DSGN) were sold and 2,296,265 shares were bought by its insiders, resulting in a net purchase of 1,481,391 shares.

Design Therapeutics Inc (DSGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Design Therapeutics Inc Insider Transactions

No Available Data

What does MoonLake Immunotherapeutics do?

Who are the key executives at MoonLake Immunotherapeutics?

Bihua Chen is the 10 percent owner of MoonLake Immunotherapeutics. Other key executives at MoonLake Immunotherapeutics include director & 10 percent owner Biotechnology Value Fund L P , director & Chief Executive Officer Santos Da Silva Jorge , and Chief Scientific Officer Kristian Reich .

MoonLake Immunotherapeutics (MLTX) Insider Trades Summary

Over the past 18 months, Bihua Chen made 3 insider transaction in MoonLake Immunotherapeutics (MLTX) with a net purchase of 802,051. Other recent insider transactions involving MoonLake Immunotherapeutics (MLTX) include a net sale of 200,000 shares made by Kristian Reich , a net sale of 184,740 shares made by Santos Da Silva Jorge , and a net sale of 2,000,000 shares made by Biotechnology Value Fund L P .

In summary, during the past 3 months, insiders sold 2,171,000 shares of MoonLake Immunotherapeutics (MLTX) in total and bought 0 shares, with a net sale of 2,171,000 shares. During the past 18 months, 2,655,740 shares of MoonLake Immunotherapeutics (MLTX) were sold and 802,051 shares were bought by its insiders, resulting in a net sale of 1,853,689 shares.

MoonLake Immunotherapeutics (MLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

MoonLake Immunotherapeutics Insider Transactions

No Available Data

What does Monte Rosa Therapeutics Inc do?

Who are the key executives at Monte Rosa Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Monte Rosa Therapeutics Inc. Other key executives at Monte Rosa Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , Principal Accounting Officer Edmund Dunn , and General Counsel Philip Nickson .

Monte Rosa Therapeutics Inc (GLUE) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Monte Rosa Therapeutics Inc (GLUE). Other recent insider transactions involving Monte Rosa Therapeutics Inc (GLUE) include a net sale of 1,857,674 shares made by Versant Venture Capital Vi, L.p. , and a net sale of 2,817 shares made by Edmund Dunn .

In summary, during the past 3 months, insiders sold 1,857,674 shares of Monte Rosa Therapeutics Inc (GLUE) in total and bought 0 shares, with a net sale of 1,857,674 shares. During the past 18 months, 1,860,491 shares of Monte Rosa Therapeutics Inc (GLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,860,491 shares.

Monte Rosa Therapeutics Inc (GLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Monte Rosa Therapeutics Inc Insider Transactions

No Available Data

What does BioAtla Inc do?

Who are the key executives at BioAtla Inc?

Bihua Chen is the director & 10 percent owner of BioAtla Inc. Other key executives at BioAtla Inc include director & 10 percent owner & Chief Executive Officer Short Jay M Phd , See Remarks Christian Vasquez , and director & President Scott Andrew Smith .

BioAtla Inc (BCAB) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in BioAtla Inc (BCAB). Other recent insider transactions involving BioAtla Inc (BCAB) include a net purchase of 6,000 shares made by Sylvia Mcbrinn , a net purchase of 50,000 shares made by Short Jay M Phd , and a net purchase of 20,000 shares made by Lawrence Steinman .

In summary, during the past 3 months, insiders sold 0 shares of BioAtla Inc (BCAB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioAtla Inc (BCAB) were sold and 83,495 shares were bought by its insiders, resulting in a net purchase of 83,495 shares.

BioAtla Inc (BCAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioAtla Inc Insider Transactions

No Available Data

What does Vigil Neuroscience Inc do?

Who are the key executives at Vigil Neuroscience Inc?

Bihua Chen is the 10 percent owner of Vigil Neuroscience Inc. Other key executives at Vigil Neuroscience Inc include director & President and CEO Ivana Magovcevic-liebisch , Chief Medical Officer Christopher Silber , and Chief Science Officer Gray David L. F. .

Vigil Neuroscience Inc (VIGL) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Vigil Neuroscience Inc (VIGL). Other recent insider transactions involving Vigil Neuroscience Inc (VIGL) include a net purchase of 4,000 shares made by Ivana Magovcevic-liebisch ,

In summary, during the past 3 months, insiders sold 0 shares of Vigil Neuroscience Inc (VIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Vigil Neuroscience Inc (VIGL) were sold and 4,000 shares were bought by its insiders, resulting in a net purchase of 4,000 shares.

Vigil Neuroscience Inc (VIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Vigil Neuroscience Inc Insider Transactions

No Available Data

What does Biomea Fusion Inc do?

Who are the key executives at Biomea Fusion Inc?

Bihua Chen is the director & 10 percent owner of Biomea Fusion Inc. Other key executives at Biomea Fusion Inc include Chief Financial Officer Franco Valle , Chief Medical Officer Juan Pablo Frias , and 10 percent owner A2a Pharmaceuticals, Inc. .

Biomea Fusion Inc (BMEA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Biomea Fusion Inc (BMEA). Other recent insider transactions involving Biomea Fusion Inc (BMEA) include a net sale of 400,000 shares made by A2a Pharmaceuticals, Inc. , a net purchase of 12,509 shares made by Franco Valle , and a net purchase of 10,000 shares made by Hitchcock Michael J.m. .

In summary, during the past 3 months, insiders sold 0 shares of Biomea Fusion Inc (BMEA) in total and bought 10,000 shares, with a net purchase of 10,000 shares. During the past 18 months, 400,000 shares of Biomea Fusion Inc (BMEA) were sold and 22,509 shares were bought by its insiders, resulting in a net sale of 377,491 shares.

Biomea Fusion Inc (BMEA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Biomea Fusion Inc Insider Transactions

No Available Data

What does Verve Therapeutics Inc do?

Who are the key executives at Verve Therapeutics Inc?

Bihua Chen is the director & 10 percent owner of Verve Therapeutics Inc. Other key executives at Verve Therapeutics Inc include See Remarks Andrew D. Ashe , Chief Administrative Officer Joan Nickerson , and director & 10 percent owner Krishna Yeshwant .

Verve Therapeutics Inc (VERV) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Verve Therapeutics Inc (VERV). Other recent insider transactions involving Verve Therapeutics Inc (VERV) include a net purchase of 1,800,000 shares made by Krishna Yeshwant , a net purchase of 76,000 shares made by Andrew D. Ashe , and a net sale of 1,514 shares made by Joan Nickerson .

In summary, during the past 3 months, insiders sold 0 shares of Verve Therapeutics Inc (VERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,068 shares of Verve Therapeutics Inc (VERV) were sold and 1,876,000 shares were bought by its insiders, resulting in a net purchase of 1,873,932 shares.

Verve Therapeutics Inc (VERV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verve Therapeutics Inc Insider Transactions

No Available Data

What does Ventyx Biosciences Inc do?

Who are the key executives at Ventyx Biosciences Inc?

Bihua Chen is the 10 percent owner of Ventyx Biosciences Inc. Other key executives at Ventyx Biosciences Inc include director & Chief Executive Officer Raju Mohan , Chief Financial Officer Martin Auster , and Chief Scientific Officer John Nuss .

Ventyx Biosciences Inc (VTYX) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Ventyx Biosciences Inc (VTYX). Other recent insider transactions involving Ventyx Biosciences Inc (VTYX) include a net sale of 573,232 shares made by Somu Subramaniam , a net sale of 573,232 shares made by Nsv Partners Iii Lp , and a net sale of 71,074 shares made by William J. Sandborn .

In summary, during the past 3 months, insiders sold 0 shares of Ventyx Biosciences Inc (VTYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,675,810 shares of Ventyx Biosciences Inc (VTYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,675,810 shares.

Ventyx Biosciences Inc (VTYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ventyx Biosciences Inc Insider Transactions

No Available Data

What does Tyra Biosciences Inc do?

Who are the key executives at Tyra Biosciences Inc?

Bihua Chen is the 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Chief Financial Officer Alan Fuhrman , director & Chief Executive Officer Todd Harris , and Chief Operating Officer Daniel Bensen .

Tyra Biosciences Inc (TYRA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 239,292 shares made by Daniel Bensen , a net sale of 370,700 shares made by Todd Harris , and a net sale of 138,711 shares made by Nina S Kjellson .

In summary, during the past 3 months, insiders sold 288,711 shares of Tyra Biosciences Inc (TYRA) in total and bought 9,500 shares, with a net sale of 279,211 shares. During the past 18 months, 748,703 shares of Tyra Biosciences Inc (TYRA) were sold and 9,500 shares were bought by its insiders, resulting in a net sale of 739,203 shares.

Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tyra Biosciences Inc Insider Transactions

No Available Data

What does Kineta Inc do?

Who are the key executives at Kineta Inc?

Bihua Chen is the director & 10 percent owner of Kineta Inc. Other key executives at Kineta Inc include director & Chief Executive Officer Shawn Iadonato , President Craig W. Philips , and General Counsel Pauline Kenny .

Kineta Inc (KANT) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Kineta Inc (KANT). Other recent insider transactions involving Kineta Inc (KANT) include a net purchase of 7,250 shares made by Raymond J. Bartoszek , a net purchase of 15,000 shares made by Shawn Iadonato , and a net purchase of 10,000 shares made by Keith Baker .

In summary, during the past 3 months, insiders sold 0 shares of Kineta Inc (KANT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Kineta Inc (KANT) were sold and 50,250 shares were bought by its insiders, resulting in a net purchase of 50,250 shares.

Kineta Inc (KANT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Kineta Inc Insider Transactions

No Available Data

What does Ambrx Biopharma Inc do?

Who are the key executives at Ambrx Biopharma Inc?

Bihua Chen is the 10 percent owner of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include 10 percent owner Cormorant Asset Management, Lp , Chief Financial Officer Sonja Nelson , and director & President and CEO Daniel J. O'connor .

Ambrx Biopharma Inc (AMAM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ambrx Biopharma Inc (AMAM) were sold and 2,152,738 shares were bought by its insiders, resulting in a net purchase of 2,152,738 shares.

Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ambrx Biopharma Inc Insider Transactions

No Available Data

What does GreenLight Biosciences Holdings PBC do?

Who are the key executives at GreenLight Biosciences Holdings PBC?

Bihua Chen is the other: See below of GreenLight Biosciences Holdings PBC. Other key executives at GreenLight Biosciences Holdings PBC include other: See remarks Mls Capital Fund Ii Lp , other: Member of 10% owner group Marta Ortega-valle , and other: Member of 13D Group Montealegre Lacayo Jaime Javier .

GreenLight Biosciences Holdings PBC (GRNA) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in GreenLight Biosciences Holdings PBC (GRNA). Other recent insider transactions involving GreenLight Biosciences Holdings PBC (GRNA) include a net sale of 9,188,659 shares made by Cormorant Global Healthcare Master Fund, Lp ,

In summary, during the past 3 months, insiders sold 0 shares of GreenLight Biosciences Holdings PBC (GRNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 9,188,659 shares of GreenLight Biosciences Holdings PBC (GRNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 9,188,659 shares.

GreenLight Biosciences Holdings PBC (GRNA)'s detailed insider trading history can be found in Insider Trading Tracker table.

GreenLight Biosciences Holdings PBC Insider Transactions

No Available Data

What does Environmental Impact Acquisition Corp do?

Who are the key executives at Environmental Impact Acquisition Corp?

Bihua Chen is the other: See below of Environmental Impact Acquisition Corp. Other key executives at Environmental Impact Acquisition Corp include director & 10 percent owner Matthew Allen Walker , other: Member of 10% owner group Marta Ortega-valle , and other: Member of 13D Group Montealegre Lacayo Jaime Javier .

Environmental Impact Acquisition Corp (ENVIU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Environmental Impact Acquisition Corp (ENVIU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Environmental Impact Acquisition Corp (ENVIU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Environmental Impact Acquisition Corp (ENVIU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Environmental Impact Acquisition Corp Insider Transactions

No Available Data

What does Ambrx Biopharma Inc do?

Who are the key executives at Ambrx Biopharma Inc?

Bihua Chen is the 10 percent owner of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include Chief Financial Officer Sonja Nelson , director & President and CEO Daniel J. O'connor , and 10 percent owner Cormorant Asset Management, Lp .

Ambrx Biopharma Inc (AMAM) Insider Trades Summary

Over the past 18 months, Bihua Chen made no insider transaction in Ambrx Biopharma Inc (AMAM). Other recent insider transactions involving Ambrx Biopharma Inc (AMAM) include a net purchase of 1,307,311 shares made by Cormorant Asset Management, Lp , a net sale of 50,012 shares made by Daniel J. O'connor , and a net sale of 12,778 shares made by Sonja Nelson .

In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 62,790 shares of Ambrx Biopharma Inc (AMAM) were sold and 1,307,311 shares were bought by its insiders, resulting in a net purchase of 1,244,521 shares.

Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Ambrx Biopharma Inc Insider Transactions

No Available Data

Bihua Chen Mailing Address

Above is the net worth, insider trading, and ownership report for Bihua Chen. You might contact Bihua Chen via mailing address: C/o Cormorant Asset Management, Lp, 200 Clarendon Street, 52nd Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.